Is there a role for secondary CMV prophylaxis in solid organ transplant patients?  

I do not think that secondary prophylaxis (SP) should be used routinely in solid organ transplant patients (SOTPs) after an episode of CMV disease. There is a fairly good retrospective study of SP with Valganciclovir (VGCV) that found no real benefit (Gardiner et al., PMID 29020220). There are some ...